ストックスクリーナーアプリを入手
8.215
0.80%
0.075
前日終値:
$8.14
開ける：
$8.15
24時間の取引高:
1.19M
Relative Volume:
0.20
時価総額：
$2.48B
収益：
$32.77M
当期純損益:
$-440.22M
株価収益率:
-3.6674
EPS:
-2.24
ネットキャッシュフロー:
$-400.48M
1週間 パフォーマンス:
-4.48%
1か月 パフォーマンス:
-17.29%
6か月 パフォーマンス:
-20.49%
1年 パフォーマンス:
+58.70%
1日の値動き範囲:
$7.98
$8.265
1週間の範囲:
$7.98
$8.70
52週間の値動き範囲:
$5.24
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IOVA | 8.22 | 2.48B | 32.77M | -440.22M | -400.48M | -2.24 |
| VRTX | 447.05 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.92 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
Long Term Trading Analysis for (IOVA) - Stock Traders Daily
Perceptive Advisors LLC's Strategic Acquisition in Iovance Bioth - GuruFocus.com
Iovance Biotherapeutics director Maynard sells $503k in stock - Investing.com
IOVA (Iovance Biotherapeutics) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Australia
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Iovance Biotherapeutics Q3: A Beat, But A SelloffNow A Buy Opportunity - Seeking Alpha
HC Wainwright Has Positive Outlook for IOVA FY2027 Earnings - MarketBeat
Earnings call: Iovance reported a third-quarter product revenue of $58.6 million - Investing.com India
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance UK
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript - Insider Monkey
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap DownTime to Sell? - MarketBeat
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlig - GuruFocus.com
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Q3 Earnings Estimate for IOVA Issued By HC Wainwright - MarketBeat
Iovance Biotherapeutics’ Strong Q3 2024 Performance - TipRanks
Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance - MSN
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Iovance Biotherapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 - GlobeNewswire
Iovance Biotherapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK
Iovance Q3 Revenue Surges to $58.6M as Amtagvi Launch Gains Momentum | IOVA Stock News - StockTitan
A Peek at Iovance Biotherapeutics's Future Earnings - Benzinga
HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday - MarketBeat
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 - The Manila Times
Iovance Biotherapeutics to Host Third Quarter and - GlobeNewswire
(IOVA) Trading Report - Stock Traders Daily
Is Iovance Biotherapeutics Stock a Buy Now? - MSN
Why Iovance Biotherapeutics (IOVA) Stock is Moving Today - GuruFocus.com
Why Iovance Biotherapeutics Stock Triumphed on Thursday - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.5%Time to Buy? - MarketBeat
Smart Money Is Betting Big In IOVA Options - Benzinga
Iovance Biotherapeutics (NASDAQ:IOVA) Now Covered by Analysts at UBS Group - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Investors Purchase High Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA) - MarketBeat
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc - Yahoo Finance
First Week of October 18th Options Trading For Iovance Biotherapeutics - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.7%Should You Buy? - MarketBeat
Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? - Insider Monkey
8 Most Promising Stocks to Buy According to Wall Street Analysts - Insider Monkey
Tumor Infiltrating Lymphocyte (TIL) Market Development Status 2034 |Iovance Biotherapeutics, Optera Therapeutics Corp, T – IndiaPolitics.com - IndiaPolitics.com
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? - Insider Monkey
Iovance Biotherapeutics (FRA:2LB) Debt-to-EBITDA : -0.22 (As of Jun. 2024) - GuruFocus.com
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):